To promote the nucleic acid therapeutics CDMO business, establish subsidiary NuChord (as of September 1, 2026, capital 200 million yen, 100% equity). Build a one-stop production system utilizing the new building and cleanrooms at the Koriyama Plant, aiming to provide services to domestic and international customers. Expected minimal impact on the consolidated results for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4112","jir_company_name":"Hubotani Chemical Industry Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4112-20260902-01.pdf","jir_short_summary":"To promote the nucleic acid therapeutics CDMO business, establish subsidiary NuChord (as of September 1, 2026, capital 200 million yen, 100% equity). Build a one-stop production system utilizing the new building and cleanrooms at the Koriyama Plant, aiming to provide services to domestic and international customers. Expected minimal impact on the consolidated results for the fiscal year ending March 2027.","jir_summary":"### Purpose of Establishment and Business Concept\nThis announces the establishment of subsidiary NuChord to enter the nucleic acid therapeutics CDMO business under the medium-term management plan CODE\/CHORD 2030. It will provide end-to-end support from raw materials to GMP manufacturing and has built a system to offer one-stop services by constructing a new building and cleanrooms at the Koriyama Plant. In light of collaboration with YGK, future considerations for joint ventures are also suggested.\n\n### Impact Going Forward and Disclosure\nThe impact on the consolidated results for the fiscal year ending March 2027 is expected to be minor, and if significant effects arise, timely disclosure will be made. While this matter does not fall under timely disclosure requirements, it is being voluntarily disclosed to provide information to investors.","jir_financial_highlights":"Capital: 2 hundred million yen (Unknown)\nEstablishment date: September 1, 2026 (Unknown)\nShareholding ratio: Our company 100% (Unknown)","jir_category":"","jir_hashtags":"#NewBusiness, #SubsidiaryEstablishment","jir_key_figures":"Capital: 2 hundred million yen\nEstablishment date: September 1, 2026\nShareholding ratio: Our company 100%","jir_meta_title":"\u3010Hubotani Chemical Industry Co., Ltd.\u3011Subsidary NuChord Established Announcement | Advancing Nucleic Acid Therapeutics CDMO","jir_meta_description":"Hodogaya Chemical Industry announces the establishment of NuChord, a new company advancing the nucleic acid therapeutics CDMO business. Capital 200 million yen, 100% ownership, facility upgrades at Koriyama Plant for one-stop service. Expected minor impact on the FY2027 consolidated results.","jir_og_title":"\u3010\u4fdd\u571f\u8c37\u5316\u5b66\u5de5\u696d\u3011Subsidary NuChord Established Announcement | Advancing Nucleic Acid Therapeutics CDMO","jir_og_description":"Announcement of the establishment of NuChord, a new subsidiary advancing the nucleic acid therapeutics CDMO business. Through equipment investment at Koriyama Plant, a continuous manufacturing system will be built. Expected minor impact on the 2027 consolidated results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56937,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-110001","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n